LASIK 5 years on…

Article

LASIK is a safe and effective procedure in the correction of myopia five years after surgery, according to a study in the September issue of Ophthalmology.

LASIK is a safe and effective procedure in the correction of myopia five years after surgery, according to a study in the September issue of Ophthalmology.

Naoko Kato and colleagues from the Minamiaoyama Eye Clinic and Keio University, Japan, examined 779 eyes of 402 patients with myopia or myopic astigmatism undergoing LASIK during a five-year period. Changes in uncorrected visual acuity (UCVA), manifest refraction, best-corrected visual acuity (BCVA), intraocular pressure (IOP), corneal thickness, corneal endothelial cell counts and complications were recorded at one week, one, three and six months, and once a year postoperatively.

UCVA improved from 1.27 preoperatively to -0.03 at one day following surgery and -0.08 at one month, with minimal but significant decreases occurring thereafter. Postoperative manifest refraction showed minimal but significant regression after one year. Final BCVA loss was seen in 10 eyes of seven patients. IOP and corneal thickness decreased by 4.0 mmHg and 76.9 µm, respectively as a result of LASIK but remained stable over the follow-up period. Corneal endothelial cell counts demonstrated a significant reduction at five years after surgery, which the researchers believe was likely to be the result of physiological age-related loss. No serious complications were observed.

It was the conclusion of the authors that LASIK is a safe and effective procedure for correcting myopia and myopic astigmatism as long as inclusion and exclusion criteria are respected. However, the researchers did point out that minimal regression is likely to occur over the five-year period.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.